Object. Gamma Knife surgery (GKS) is a treatment option for patients with refractory typical trigeminal neuralgia (TN), TN with atypical features, and atypical types of facial pain. The Gamma Knife's 201 60 Co sources decay with a half-life of 5.26 years. The authors examined whether the decrease in dose rate over 4.6 years between Co source replacements affected the control rates of facial pain in patients undergoing GKS.
ACIAL pain is a spectrum of conditions of varying clinical behavior. Typical TN, also known as tic douloureux, is characterized by a paroxysmal, electric shock-like pain in one or more of the three trigeminal nerve distributions. Some common triggers of pain include chewing, brushing one's teeth, shaving or otherwise touching the face, talking, and exposure to cold air. Trigeminal neuralgia occurs at an overall age-and sex-adjusted annual rate of 4.7 per 100,000 persons. 8 For some patients, TN has accompanying atypical features, such as burning, chronic pain, and/ or dull aching pain. Other patients may only have atypical features without any sign of the "classic" episodic, lancinating-type pain. Multiple sclerosis, herpes zoster, and trauma or surgery may result in altogether different types of facial pain.
Gamma Knife surgery, a noninvasive outpatient procedure, presents a very appealing treatment option for patients with medically refractory facial pain. The first radiosurgical procedure for TN was performed by Lars Leksell using an orthovoltage dental x-ray tube coupled with a stereotactic device. 9 The 22-ton GKS unit uses 201 60 Co sources that focus gamma radiation, with an accuracy of Ϯ 0.1 mm, onto the trigeminal nerve root entry zone tangential to the brainstem. A number of treatment-and patient-related factors have been retrospectively and prospectively evaluated to determine their influence, if any, on clinical outcomes after GKS. These factors include radiation dose, irradiated length of the trigeminal nerve root, distance of the isocenter from the brainstem, and the trigeminal nerve-blood vessel relationship. [1] [2] [3] 7, 12 Because the 201 60 Co sources used in GKS decay with a half-life of 5.26 years, the dose rate is reduced by half and the treatment duration is doubled over this period (assuming a constant prescription dose). A biological model that takes repair and dose rate into account may be used to calculate a BED for varying treatment durations and prescription doses. 10, 15 Because dose rate is inversely proportional to treatment duration and directly proportional to the prescription dose, this model allows a comparative analysis of treatment outcomes for a heterogeneous patient population. (A more detailed mathematical explanation is found in Clinical Material and Methods.) This model suggests that over the range of typical treatment times of 25 to 60 minutes, the BED may vary from 2 to 31% depending on the biological assumptions that are made in the model. Because pain control appears to improve with increasing prescription dose, 1, 12 these values suggest that clinical outcomes could vary either greatly or not at all over the period of one half-life of Co. Thus, given that the effect of dose rate in GKS treatment of TN has not been formally investigated, we attempted to examine whether the decrease in the dose rate and increase in treatment duration over approximately 4.6 years (55% of activity remaining) between Co source replacement at our institution affected the control rates of facial pain for patients undergoing GKS. A secondary goal was to determine whether the biological model had any validity in this clinical setting.
Clinical Material and Methods
Between September 1999 and March 2004, 326 GKS procedures for patients with facial pain were performed at Wake Forest University Baptist Medical Center in WinstonSalem, North Carolina. After they provided informed consent, all patients were treated by a team consisting of a radiation oncologist, a neurosurgeon, and a medical physicist using a 201 60 Co source GKS unit. The neurosurgeon applied a Leksell stereotactic head frame to the patient, who then underwent a high-resolution stereotactic magnetic resonance imaging study of the brain with administration of contrast medium. A treatment plan was generated using the Leksell GammaPlan Treatment Planning System (Elekta, Norcross, GA). The 50% isodose line was placed tangential to the brainstem, with the isocenter of a 4-mm collimator helmet targeted at the proximal trigeminal nerve root. The radiation dose was prescribed at the 100% isodose line. Barring significant medical comorbidities, most patients were discharged the day of the procedure and were requested to return for a follow-up appointment approximately 3 months later.
At the time of the analysis, charts were unobtainable for 15 patients, and these patients were excluded from data analysis. Thirty-one patients underwent repeated GKS for recurrent or persistent facial pain. For these patients, only the initial radiosurgical procedure was included in the study. Therefore, 280 patients were included in the analysis of the patient population. During follow-up review, 41 patients were unreachable by telephone; however, short-term follow-up data were available for 17 of these patients. Consequently, these patients were included in the outcome analysis, and the other 24 unreachable patients were excluded. Thus, the facial pain outcomes for 256 GKS patients were analyzed in this study.
Burchiel 4 has suggested a classification scheme for different types of facial pain encountered in neurosurgical practice, with the following categories: TN Types 1 and 2, trigeminal neuropathic pain, trigeminal deafferentation pain, symptomatic TN, postherpetic neuralgia, and atypical facial pain. In the present study, we adapted Burchiel's classification scheme to fit the medical verbiage used to describe facial pain in patient charts (Table 1) .
Short-term outcome data were generated from a chart review of the physician notes, which were dictated by either the radiation oncologist or the neurosurgeon. The follow-up notes typically were generated 1 to 6 months after treatment with GKS. The long-term follow-up data were obtained through telephone conversations with the patients. Patients self-reported data on pain control after being asked standard questions that measured pain relief after treatment (yes/no); degree of pain relief; time interval to partial and/or complete pain relief; recurrence of pain (yes/no); partial and/or complete pain-free interval; presence of complications (up to four); use of medication at 1, 2, 3, and 6 months; improvement in quality of life (yes/no); and further surgical procedures (yes/no). The degree of pain relief was recorded in four categories: excellent (complete pain relief with no medication use), good (complete pain relief with medication use), fair (50-99% pain relief with or without medication use), and poor (Ͻ 50% pain relief with or without medication use). Medication use at the time the questionnaire was filled out, relative to medication use at the time of GKS, was recorded in four categories: same, increased, decreased, and stopped. All data were entered into a Microsoft Access database created specifically for the research study.
Radiobiological Calculations
The biological model used was that developed by Thames and Nilsson 10, 15 for continuous radiation:
where D = total dose, e = the number used as the base for natural logarithms, g = continuous repair factor, 1n 2 = the logarithm of 2 with base e, ␣/␤ = the ratio of the tissue-specific linear and quadratic survival parameters specific for the linear-quadratic factor model, 11 t = exposure duration = D/dose rate, = recovery constant, and T 1/2 = repair halftime.
For several of these factors, we had to make some assumptions because exact human data were not always readily available. The ␣/␤ for neural tissue, viewed radiobiologically as a late-responding tissue, is generally thought to be low; most authors believe it ranges between 1.5 and 3. We selected 1.5 for the basis of our calculations, as this lower range is in agreement with the values reported in most of the available literature. 16 Also, T 1/2 , the repair half-time, is thought to range from 0.25 hour for a fast repair to 6.5 hours for a slow repair. We selected a value of 6.5 hours because the biological response time after treatment suggests that repair is quite slow. 13 For this value, the model is used to predict that for any given prescription dose, the BED remains essentially unchanged over one half-life of the Gamma Knife unit sources. Table 2 shows, as an illustrative example, the anticipated changes in BED for various values of and T 1/2 at a fixed prescription dose of 85 Gy.
Statistical Analysis
An evaluation of treatment time and dose rate could not be performed without taking into account multiple potentially confounding variables. To investigate the effect of dose on the probability of treatment success, we fit logistic models with dose as a categorical linear term separately for each of the three most common pain types (typical TN/Type 1, TN with atypical features/Type 2, and atypical facial pain). We also fit logistic models including dose as either a categorical or a linear term, as well as type of pain and the associated interactions. When models were fit with a categorical dose term, only the three most common doses, 80, 85, and 90 Gy, delivered with a single isocenter (94.2% of all patients) were used. Models with a linear dose term used all observations. Wald probability values are reported. We performed contingency table analysis using the Fisher exact test on the 2 ϫ 3 table of success (yes/no) versus dose (80, 85, and 90 Gy) for each of the three most common pain types.
For those patients who experienced successful treatment, time to pain recurrence was defined as the interval from complete pain relief to less-than-complete pain relief. If the patient was still pain free at the time of follow up, that patient was censored. Two types of analyses were performed. One used only those patients who experienced complete pain relief. The other used all patients and took the time to pain recurrence for those who never had complete pain relief to be 1 day. To investigate the effect of dose on the time to pain recurrence, we fit Cox proportional hazards models with dose as a categorical term or as a linear term separately for each of the three most common pain types. We also fit Cox proportional hazards models including type of pain in addition to dose as either a categorical or a linear term. When models were fit with a categorical dose term, only the three most common doses, 80, 85, and 90 Gy, delivered with a single isocenter (94.2% of all patients) were used. Models with a linear dose term used all observations. We used the Efron method of handling ties in event times. Likelihood ratio test probability values are reported.
Finally, for the purpose of estimating how much the BED might vary over our typical treatment durations, we took excellent, good, or fair pain relief as a response. Logistic regression was used to model the logit of response as a function of treatment time. The resulting coefficient was converted to an estimated probability of response at the range of typical treatment duration, 25 and 60 minutes. These estimated probabilities were then compared to yield the estimated difference of BED from 25 to 60 minutes.
Results

Pretreatment Patient Characteristics
Women (63%) outnumbered men in the study. The median age of patients at the time of GKS was 65 years (range 22-90 years). Patients had experienced facial pain for a median of 5 years (range 0.2-50 years) before GKS. Six types of pain were represented: typical TN (172 patients), TN with atypical features (42 patients), atypical facial pain (20 patients), trigeminal neuropathic pain (eight patients), symptomatic TN (eight patients), and postherpetic neuralgia (six patients). There were no patients with trigeminal deafferentiation pain as described by Burchiel. 4 Table 3 displays the maximum prescription dose for patients treated with either one or two shots at the time of GKS. In the study, 240 patients were treated with one isocenter using the 4-mm collimator helmet. The majority of these patients (49%) received 90 Gy prescribed at the 100% isodose line; the other patients received 80 Gy (25%), 85 Gy (20%), or another dose (5.9%). A total of 37 patients were treated with a concentric two-isocenter technique that involved one isocenter with a combination of the 4-and 8-mm collimator helmets. Of the patients treated with this technique, 70% received a prescription dose of 85 Gy and 30% received 90 Gy. An additional three patients were treated with two adjacent 4-mm isocenters, with one patient (33%) each at 80, 85, and 90 Gy. Dose calculations for the first five patients (up to February 15, 2000) were based on a 4-mm collimator output factor of 0.835, whereas dose calculations for the remaining 275 patients were based on a 4-mm collimator output factor of 0.87. 17 For this study, we adjusted the prescription dose (factor = 0.87/0.835) for the first five patients, to account for this difference.
Radiation Dosimetry
Follow-Up Review
A total of 239 patients were reached by telephone to complete the long-term follow up. Short-term follow-up data were available for 17 of the 41 unreachable patients. Therefore, a total of 256 patients were used in the analysis of the facial pain outcome data. Table 4 illustrates both the mean and median duration of follow up for the overall patient population and each type of pain. The overall median follow-up period was 17 months (range 0.7-59 months). Patients with typical TN underwent the longest median follow up (18 months), whereas patients with trigeminal neuropathic pain underwent the shortest median follow up (9.5 months).
Success Rate
We evaluated the percentage of success (at last follow up) according to dose and type of pain. Analysis of the dose effect yielded no statistically significant findings. Table 5 shows the overall control rates by type of pain. The categorical dose term probability values were 0.1, 0.8, and 0.7, respectively, for the logistic models in patients with typical TN/Type 1, atypical features/Type 2, and atypical facial pain. In the model including type of pain and associated interactions, the categorical dose term probability value was 0.1, and the interaction probability value was 0.8. The linear dose term probability values were 0.2, 0.4, and 0.6, respectively, for the logistic models in patients with typical TN/Type 1, atypical features/Type 2, and atypical facial pain. In the model including type of pain and associated interactions, the linear dose term probability value was 0.2, and the interaction probability value was 0.4. The contingency-table Fisher exact probability values were 0.1, 0.8, and 0.8, respectively, for patients with typical TN/Type 1, atypical features/Type 2, and atypical facial pain. Figure 1 shows the Kaplan-Meier curve for time to pain recurrence for all patients who experienced complete pain relief. Table 6 depicts the median time to pain relief for patients who experienced both complete and partial pain relief. Complete pain relief represents both "excellent" and "good" facial pain outcomes. Partial pain relief represents the "fair" facial pain outcome. Overall, the median time to either complete (143 patients) or partial (61 patients) pain relief was 4 weeks; the range was 0.1 to 87 and 0.1 to 28 weeks, respectively. Among those patients who experienced some degree of pain relief, there was no significant difference in the median time to pain relief between any of the pain categories. Overall, the median pain-free interval was not reached during the follow-up period in this study. ‡ QOL = quality of life improvement, self-reported from patient in yes/no format (overall, 239 patients; typical TN, 159 patients; TN with atypical features, 41 patients; atypical facial pain, 19 patients; symptomatic TN, six patients; trigeminal neuropathic pain, eight patients; and postherpetic neuralgia, six patients).
Time to Pain Relief and Recurrence
Effect of Dose Rate and Treatment Time on the Control Rate of Facial Pain
the GKS unit, the dose rate decreased over time from 3.627 Gy/minute (September 7, 1999) to 2.001 Gy/minute (March 26, 2004) . As seen in Fig. 2 , physicians prescribed higher doses near the end of the study in comparison with those prescribed at the start of the study. Figure 3 shows that the treatment duration increased in a relatively linear fashion over this period, with some minor fluctuation due to changes in prescription dose. The patients with long treatment durations, represented by the four outliers in Fig. 3 , all received a typical prescription dose (as seen in Fig. 2) . Two of the patients were treated with two isocenters, in which one isocenter's contribution was very low (0.7 and 2.4%), creating an artificially long treatment duration. The other two patients' treatment durations were increased due to an increased attenuation correction factor built into the dose rate at the isocenter. Neither dose rate nor treatment time was significantly associated with either the control rate or the degree of pain relief. This held true for the overall population of patients as well as for each category of type of pain. Figure 4 shows the relationship of the calculated BED to the dose rate for the three most commonly used prescription doses. This leads us to suggest that, based on the biological parameters we chose, the model appeared to predict accurately that the relative biological efficacy would remain essentially constant for a fixed prescription dose, regardless of the dose rate of the period of one half-life.
Discussion
In this study, our goal was to examine the relationship of dose rate and treatment duration to facial pain control in patients undergoing GKS. Neither a declining dose rate nor an escalating treatment duration was associated with the rate of facial pain control or the degree of pain relief for patients undergoing GKS. In our analysis, this held true for the overall patient population and for each individual type of pain. We recognize that, in a small number of patients, we may have classified somatoform pain disorder as TN. We do not know if a placebo effect is possible, but the fact that some of these patients responded to treatment underscores the need for further investigation into the pathophysiology of facial pain not classified as classic TN. Correlating the subjective experience of pain with functional and anatomical studies is an area of active research at our institution and other centers. 5, 6 As understanding of the subjective and objective correlation between illness and pain improves, we suspect that the somatoform category will experience a "Will Rogers effect" that will require reevaluation and validation of the Burchiel scheme. 14 In the statistical analysis of dose rate, we accounted for changes in prescription dose over time to prevent the prescription dose from being a confounding variable. Furthermore, in the treatment duration analysis, we accounted for changes in both the dose rate and prescription dose over time, to reflect that treatment time is inversely proportional to the dose rate at the isocenter and directly proportional to overall ( NA NA the prescription dose (treatment time = prescription dose/ dose rate at focus). Ultimately, it appeared that the biological model could be used to predict accurately that, given the input parameters used, there would be no significant difference in clinical outcome.
Conclusions
The present results are quite useful from a practical standpoint of patient care and economics. At Wake Forest University Baptist Medical Center, the 201 60 Co sources on the GKS are changed after each half-life, or approximately every 5 years. Because there is no observable effect of dose rate or treatment duration on the control of facial pain, patients with facial pain may be confident that they are receiving optimal care with GKS at any time during the first halflife of the Co sources.
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